Iron for Health & Longevity

Evidence Review created on 11/12/2026 using AI4L + evidence-mcp / Opus 5.5

Also known as: Iron Supplementation, Iron Supplement, Ferrous Sulfate, Ferrous Gluconate, Ferrous Fumarate, Ferrous Bisglycinate, Iron Bisglycinate, Polysaccharide-Iron Complex, Carbonyl Iron, Heme Iron Polypeptide, Ferric Maltol, Intravenous Iron, IV Iron, Ferric Carboxymaltose, Ferric Derisomaltose, Iron Isomaltoside, Iron Sucrose, Iron Dextran, Ferumoxytol, Sodium Ferric Gluconate, Injectafer, Ferinject, Monoferric, Monofer, Venofer, Feraheme, INFeD, CosmoFer, Ferrlecit, Accrufer, Feraccru, Fe

Motivation

Iron is an essential mineral that lets red blood cells carry oxygen and helps every cell turn food into energy. Unlike most nutrients, the body has no active way to get rid of it, so the amount stored depends on how much is absorbed and how much blood is lost. That makes iron a two-sided question for anyone focused on a long, healthy life: both too little and too much draw concern.

Low iron is the most common nutritional shortfall worldwide, especially among menstruating women, endurance athletes, frequent blood donors and people on plant-based diets. At the same time, iron stores build up with age in men and after menopause in women, and genetic studies asking whether naturally higher iron levels affect lifespan have drawn attention from the longevity community. Tablets are cheap and sold without a prescription, while infusions are given in clinics.

This review examines what the evidence shows about taking iron, by mouth or by infusion, for fatigue, heart health and lifespan; which people stand to gain or lose; how dosing and testing shape that balance; and where the evidence remains uncertain.

Benefits - Risks - Protocol - Conclusion

Expert commentary and overviews on iron deficiency, iron overload and aging from longevity-focused practitioners and researchers.

Huberman Lab has no dedicated content on iron; it touches ferritin only briefly within an episode on female athletes (Dr. Stacy Sims: Female-Specific Exercise & Nutrition for Health, Performance & Longevity), too brief to qualify as an item.

Grokipedia

Iron supplement

AI-generated overview of supplement forms, recommended intakes, the 45 mg daily upper limit, absorption enhancers and inhibitors, and intravenous options; useful for orientation, not as a primary source.

Examine

Iron benefits, dosage, and side effects

Summarizes iron forms, studied doses of 1 to 300 mg of elemental iron (the iron content itself, not the salt weight) and alternate-day schedules; graded evidence across 17 outcomes sits mostly behind the Examine+ paywall.

ConsumerLab

Iron Supplements Review (Iron Pills, Liquids and Chews)

Independent laboratory testing of iron products for labeled content and purity, with guidance on forms, fatigue and reducing digestive side effects; full results and Top Picks require membership.

Systematic Reviews

Five systematic reviews and meta-analyses covering iron’s main benefits in adults and its principal adverse effect.

Mechanism of Action

Iron sits at the center of hemoglobin and of myoglobin (the oxygen store in muscle), and of mitochondrial enzymes that turn food into energy. It is also needed to make DNA and the brain messenger dopamine.

  • Absorption: Food and supplement iron enters gut cells through DMT1 (divalent metal transporter 1, the main iron entry channel), leaves them through ferroportin (the only known cellular iron exporter), travels in blood bound to transferrin (the iron transport protein) and is stored as ferritin.
  • Regulation by hepcidin: Hepcidin (a liver hormone) blocks ferroportin. A daily oral dose raises hepcidin and lowers absorption from the next day’s dose (Stoffel 2017). Inflammation also raises hepcidin, limiting oral iron absorption, as a Lancet review summarizes (Pasricha 2021).
  • No excretion route: The body loses iron only through bleeding and shed cells, so absorbed excess accumulates.
  • Competing view, iron as an aging driver: Free iron reacts with hydrogen peroxide (the Fenton reaction) to form damaging hydroxyl radicals and can trigger ferroptosis (iron-dependent cell death). A theory review argues that iron accumulates with aging (Mangan 2021) and that blocking its absorption extends lifespan in model organisms (Mangan 2021).
  • Pharmacological properties: Iron is a mineral: it acts as a cofactor without receptor selectivity, with no liver enzyme metabolism or CYP (cytochrome P450 drug-metabolizing enzyme) interactions. Body iron has no elimination half-life; intravenous ferric carboxymaltose clears from plasma with a terminal half-life of 7–12 hours (Injectafer label). Absorbed iron is distributed mainly to hemoglobin, liver and marrow.

Historical Context & Evolution

Iron was first used to treat chlorosis (the “green sickness” of pale, tired young women, now recognized as iron-deficiency anemia). Thomas Sydenham prescribed iron filings steeped in wine in the 17th century, and Blaud’s ferrous sulfate preparation followed in 1832. Ferrous sulfate became the global standard in the 20th century, and intravenous preparations arrived later, from iron dextran to modern complexes such as ferric carboxymaltose.

Interest moved beyond anemia in two opposite directions. One asked whether iron helps people who are low but not anemic, prompting trials of fatigue and athletic performance. The other asked whether iron harms people who are not low. Sullivan’s 1981 “iron hypothesis” proposed that higher stored iron explains why men and postmenopausal women have more heart disease than premenopausal women (Sullivan 1981). In Finland’s Kuopio cohort, men with ferritin of at least 200 μg/L had a 2.2-fold risk of acute myocardial infarction (MI, heart attack) (Salonen 1992). A meta-analysis of later cohorts found them inconsistent (Danesh 1999), and the FeAST trial, which lowered iron by regular blood removal in peripheral arterial disease (PAD, narrowed leg arteries), found no significant mortality reduction (Zacharski 2007).

Since 2020, genetic studies have revived the question; one linked genetically higher serum iron to shorter parental lifespan (Daghlas 2021). Manufacturer-funded heart failure trials of intravenous iron produced positive (Vifor’s FAIR-HF; Anker 2009) and neutral (American Regent’s HEART-FID; Mentz 2023) results. Neither line has settled whether healthy adults with normal iron gain or lose from extra iron.

Expected Benefits

High 🟩 🟩 🟩

Correction of iron deficiency and anemia

Restoring hemoglobin and iron stores is the core benefit and underlies most others. A Cochrane review by Low pooled 67 trials in menstruating women from many independent groups, including Hinton and Gordeuk in the USA and Elwood in the UK (Low 2016). In a meta-analysis of older adults with iron-deficiency anemia, oral iron raised hemoglobin in three trials (Tay 2015). For health-focused adults the benefit is confined to confirmed deficiency; people with normal stores gain nothing measurable.

Magnitude: Anemia at the end of treatment was less likely with iron than control: RR (risk ratio, the risk with iron relative to control) 0.39, 95% CI (confidence interval, the range likely to contain the true effect) 0.25–0.60 (Low 2016), and hemoglobin was 5.30 g/L higher (95% CI 4.14–6.45) (Low 2016); in older adults hemoglobin rose 0.35 g/dL more than placebo or no treatment (95% CI 0.12–0.59) (Tay 2015).

Reduced restless legs symptoms

Restless legs syndrome (an urge to move the legs, worse at rest and at night) is linked to low brain iron. A Cochrane review pooled placebo-controlled trials from independent groups (Trotti 2019) led by Wang (oral ferrous sulfate; Wang 2009), Allen and Trenkwalder (intravenous ferric carboxymaltose; Allen 2011, Trenkwalder 2017) and Earley (iron sucrose; Earley 2009). Four trials were funded by the companies selling the iron tested (Trotti 2019). Subjective sleep quality did not differ from placebo (Trotti 2019).

Magnitude: Iron improved IRLS (International Restless Legs Scale, 0–40) scores by 3.78 points more than placebo (95% CI 1.31–6.25) (Trotti 2019).

Fewer heart failure hospitalizations with intravenous iron ⚠️ Conflicted

Groups led by Anker (FAIR-HF2, co-funded by maker CSL Vifor; Anker 2025), Kalra (IRONMAN, co-funded by maker Pharmacosmos; Kalra 2022) and Mentz (HEART-FID, funded by maker American Regent; Mentz 2023) tested intravenous iron. HEART-FID found no apparent difference on its composite of death, hospitalization and walking distance (Mentz 2023), and FAIR-HF2 did not significantly reduce total heart failure hospitalizations (Anker 2025). A six-trial meta-analysis found effects greatest in year one, when doses are highest (Anker 2025). Net, pooled trials favor intravenous iron for heart failure hospitalization.

Magnitude: Recurrent heart failure hospitalization or cardiovascular death at 12 months RR 0.72 (95% CI 0.55–0.89) versus placebo (Anker 2025).

Fewer blood transfusions with intravenous iron ⚠️ Conflicted

Raising hemoglobin lowers the need for donor red blood cells. A meta-analysis by Litton’s group found fewer transfusions with intravenous iron than with oral or no iron (Litton 2013), as did an independent one by Shah’s group (Shah 2021). A Cochrane review of four small preoperative trials found no reduction (Ng 2019). Net, the larger analyses favor intravenous iron for avoiding transfusion, alongside the infection signal under Risks.

Magnitude: Red blood cell transfusion RR 0.83 (95% CI 0.76–0.89; corrected in a 2024 erratum) versus oral or no iron (Shah 2021); RR 0.74 (95% CI 0.62–0.88) (Litton 2013); preoperative trials RR 1.21 (95% CI 0.87–1.70) versus placebo, no treatment or standard care (Ng 2019).

Medium 🟩 🟩

Better exercise capacity in iron deficiency ⚠️ Conflicted

Pasricha’s meta-analysis found daily oral iron raised maximal oxygen uptake in premenopausal women across 22 trials, only 3 rigorously designed (Pasricha 2014). In heart failure, Sindone’s Vifor-funded 12-trial meta-analysis found intravenous iron improved walking distance (Sindone 2023) and peak oxygen uptake (Sindone 2023). Houston’s systematic review found no change in maximal oxygen uptake in non-anemic iron-deficient adults (Houston 2018), nor did oral iron in heart failure (Lewis 2017). Graded Medium: few rigorous trials; heart failure trials mostly one group. Net, gains appear where deficiency limits oxygen delivery.

Magnitude: Relative maximal oxygen uptake rose 2.35 mL/kg/min more than control (95% CI 0.82–3.88) (Pasricha 2014), and heart rate at set workloads was 4.05 beats per minute lower (95% CI 0.85–7.25) (Pasricha 2014); in heart failure, 6-minute walk distance rose 36.1 m more than control (95% CI 34.2–38.0) (Sindone 2023); in non-anemic adults, SMD (standardized mean difference, effect size in standard-deviation units) 0.11 (95% CI −0.15 to 0.37) (Houston 2018).

Less fatigue in iron-deficient women without anemia ⚠️ Conflicted

Low ferritin can cause fatigue without anemia. Oral ferrous sulfate reduced fatigue in non-anemic women in a Swiss trial (Verdon 2003) and a French trial (Vaucher 2012) by one Lausanne-based group, funded by tablet makers Robapharm and Pierre Fabre; a Vifor-funded intravenous iron trial showed a non-significant overall fatigue reduction (Krayenbuehl 2011) and helped only at ferritin ≤15 ng/mL (Krayenbuehl 2011). In Verdon’s trial, only women with ferritin ≤50 μg/L improved (Verdon 2003). Graded Medium: the positive trials share one group. Net, pooled trials show a modest effect (Houston 2018).

Magnitude: The fatigue score fell 47.7% with iron and 28.8% with placebo (difference −18.9%, 95% CI −34.5 to −3.2) (Vaucher 2012); pooled SMD −0.38 (95% CI −0.52 to −0.23) (Houston 2018).

Attention and memory in iron-deficient young people and women ⚠️ Conflicted

Iron is needed for brain energy and neurotransmitter synthesis. In a meta-analysis, iron improved attention and concentration in older children, adolescents and women (Falkingham 2010); no trials in men or older people were found (Falkingham 2010). A later meta-analysis in non-anemic participants found improved short-term memory (Fiani 2025) but not attention (Fiani 2025). Trials were small and short. Net, modest cognitive gains appear in iron-deficient groups, with no evidence in older adults.

Magnitude: Attention and concentration SMD 0.59 (95% CI 0.29–0.90) (Falkingham 2010), and IQ (intelligence quotient) 2.5 points higher in anemic groups (95% CI 1.24–3.76) (Falkingham 2010); short-term memory effect size d 0.53 in non-anemic randomized trials (Fiani 2025).

Better heart failure symptoms and quality of life with intravenous iron ⚠️ Conflicted

Iron deficiency worsens breathlessness and fatigue in heart failure. Sindone’s meta-analysis, funded by ferric carboxymaltose maker Vifor, found intravenous iron improved NYHA (New York Heart Association) symptom class (Sindone 2023) and quality-of-life scores (Sindone 2023). In the investigator-initiated IRONMAN trial, co-funded by Pharmacosmos, the quality-of-life gain was borderline at 4 months and not significant at 20 months (Kalra 2022). Graded Medium: the pooled trials came largely from one manufacturer-funded group led by Ponikowski and Anker. Net, intravenous iron modestly improves symptoms, with uncertain durability.

Magnitude: KCCQ (Kansas City Cardiomyopathy Questionnaire, a 0–100 symptom and quality-of-life score) 7.0 points higher than control (95% CI 6.7–7.3) (Sindone 2023) and NYHA class 1.0 lower (95% CI 0.5–1.5) (Sindone 2023); in IRONMAN, MLHFQ (Minnesota Living with Heart Failure Questionnaire, lower is better) overall score 3.33 points lower than usual care at 4 months (95% CI 0.00–6.67) (Kalra 2022).

Fewer anxiety symptoms in iron deficiency without anemia

Iron is needed to make the brain messengers that regulate mood. A meta-analysis pooling placebo-controlled randomized trials in non-anemic iron-deficient adolescents and menstruating adults found iron improved anxiety symptoms (Fiani 2025), while depression did not improve (Fiani 2025). The effect was absent when participants without iron deficiency were analyzed alone (Fiani 2025). Graded Medium: one pooled analysis of small trials, not yet replicated by an independent review.

Magnitude: Anxiety symptoms improved by effect size d 0.34 versus placebo in non-anemic randomized trials; the abstract reports no 95% CI (Fiani 2025).

Low 🟩

Lower mortality where anemia is avoided ⚠️ Conflicted

Anemia was linked to higher mortality in a US cohort (Cannon 2024), but low ferritin without anemia was not (Cannon 2024). Indirect: iron levels, not supplementation, were studied. Intravenous iron did not significantly lower mortality in a heart failure meta-analysis (Anker 2025). Net, trials do not confirm lower mortality.

Magnitude: Anemia versus normal hemoglobin, fully adjusted all-cause mortality HR (hazard ratio, relative event rate over time) 1.37 (95% CI 1.19–1.58) (Cannon 2024); intravenous iron versus placebo, all-cause mortality HR 0.92 (95% CI 0.80–1.07) (Anker 2025).

Speculative 🟨

No benefit is graded Speculative: the cell and animal rationale, such as iron-dependent mitochondrial enzymes, is already captured by the human outcome data above.

Benefit-Modifying Factors

  • Genetic variants: People with two copies of HFE C282Y (the main variant behind hereditary hemochromatosis, an inherited iron overload; it weakens the brake on iron absorption) more often develop overload-related disease (Pilling 2019), so they are least likely to benefit.
  • Baseline ferritin: Fatigue improved only in women with ferritin ≤50 μg/L (Verdon 2003); a meta-analysis in athletes found ferritin rose clearly only when it started at ≤12 µg/L (Šmid 2024).
  • Inflammation: A Lancet review notes that inflammation raises hepcidin and limits oral iron absorption, favoring intravenous iron (Pasricha 2021).
  • Sex: Menstruating women carry most of the benefit; nearly all fatigue and oral-iron exercise trials enrolled women. The same review holds that iron deficiency anemia in men and postmenopausal women warrants a search for gastrointestinal bleeding (Pasricha 2021).
  • Pre-existing conditions: Heart failure and restless legs syndrome raise the stakes; bariatric (weight-loss) surgery and actively inflamed bowel disease shift the route toward intravenous iron in American Gastroenterological Association (AGA) guidance, whose members bill for infusions (DeLoughery 2024).
  • Age: In a meta-analysis of older adults, oral iron raised hemoglobin by only 0.35 g/dL more than placebo (Tay 2015).
  • Lifestyle: Endurance athletes, frequent blood donors and people on plant-based diets are more often deficient.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Gastrointestinal side effects ⚠️ Conflicted

Oral iron, especially ferrous sulfate, causes nausea, constipation, diarrhea and abdominal pain, the main reason people stop. Unabsorbed iron irritates the gut lining. Tolkien pooled 20 placebo-controlled trials from independent groups showing more gastrointestinal side effects with ferrous sulfate (Tolkien 2015), as did Low’s Cochrane review in menstruating women, pooling trials from groups including Gordeuk, Marks and Waldvogel (Low 2016). In restless legs trials, gastrointestinal side effects were not significantly more common than with placebo (Trotti 2019). Net, the larger analyses show a clear, dose-schedule-sensitive excess.

Magnitude: Ferrous sulfate versus placebo OR (odds ratio, relative odds of the event) 2.32 (95% CI 1.74–3.08) (Tolkien 2015); hard stools or constipation RR 2.07 (95% CI 1.35–3.17) versus control (Low 2016); restless legs trials RR 1.44 (95% CI 0.76–2.75) (Trotti 2019). Event rates per group are not reported in these abstracts.

Infection with intravenous iron ⚠️ Conflicted

Bacteria need iron, and rapidly delivered iron may feed their growth. Intravenous iron was associated with more infections than oral or no iron in a meta-analysis by Shah’s group (Shah 2021) and in an independent one by Litton’s group (Litton 2013). Avni’s analysis found no increased risk of infections (Avni 2015), and in IRONMAN fewer patients given ferric derisomaltose were hospitalized for infection (Foley 2025). Net, a small excess is likely across mixed populations but not in iron-deficient heart failure.

Magnitude: Infection RR 1.16 (95% CI 1.03–1.29; corrected from 1.17 in a 2022 erratum) versus oral or no iron, 16 more infections per 1,000 (95% CI 3–29) (Shah 2021); relative risk 1.33 (95% CI 1.10–1.64) (Litton 2013); infection hospitalization in 20% with ferric derisomaltose versus 25% with usual care (HR 0.76, 95% CI 0.59–0.98 in the full-text table; the abstract gives 0.49–0.98) (Foley 2025).

Severe infusion reactions with intravenous iron

Intravenous iron can trigger infusion reactions, mostly allergy-like rather than anaphylaxis (severe whole-body allergy). In Avni’s meta-analysis of 103 trials, severe infusion reactions were more common with intravenous iron (Avni 2015), without more serious adverse events overall (Avni 2015). Kennedy’s meta-analysis, funded by ferric derisomaltose maker Pharmacosmos, found serious or severe hypersensitivity in 1.08% with ferric carboxymaltose and 0.14% with ferric derisomaltose (Kennedy 2023). The label reports serious anaphylactic-type reactions, some fatal (Injectafer label), and hypertension in 4% versus 2% with comparators (Injectafer label).

Magnitude: Severe infusion reactions RR 2.47 (95% CI 1.43–4.28) versus comparators (Avni 2015); event rates per group are not reported in the abstract.

Hypophosphatemia after ferric carboxymaltose

Ferric carboxymaltose raises FGF23 (fibroblast growth factor 23, a hormone that makes kidneys excrete phosphate), causing hypophosphatemia (low blood phosphate). Severe cases with osteomalacia (bone softening) and fractures have occurred after marketing (Injectafer label). In two randomized trials by Wolf, sponsored by ferric derisomaltose maker Pharmacosmos, hypophosphatemia was far less common with ferric derisomaltose (Wolf 2020). An independent group led by Bellos pooled eight randomized trials (5,989 patients) in a network meta-analysis with the same result (Bellos 2020). Oral iron does not cause it.

Magnitude: In trial A, hypophosphatemia occurred in 75.0% with ferric carboxymaltose versus 7.9% with iron isomaltoside (adjusted rate difference −67.0%, 95% CI −77.4% to −51.5%) (Wolf 2020); across eight trials, ferric carboxymaltose versus iron isomaltoside RR 7.90 (95% CI 2.10–28.0) (Bellos 2020).

Medium 🟥 🟥

Fatal accidental poisoning in young children

Iron tablets resemble sweets, and an overdose corrodes the gut and causes shock and liver failure. Iron poisoning was a major cause of unintentional poisoning death in children younger than 6 years (Tenenbein 2005). US products must carry an accidental-overdose warning (21 CFR 101.17). Households of adult users are the population at risk.

Magnitude: After unit-dose packaging, iron poisoning deaths in children younger than 6 fell from 29 to 1 (odds ratio 13.56, 95% CI 1.85–99.52) (Tenenbein 2005), and iron ingestion calls from 2.99 to 1.91 per 1,000 calls (Tenenbein 2005); before-after comparison, no concurrent control group.

Low 🟥

Higher mortality with higher iron status ⚠️ Conflicted

Iron supplement use predicted higher mortality in 38,772 older women (Mursu 2011). Genetically higher serum iron predicted shorter parental lifespan (Daghlas 2021); ferritin ≥200 μg/L predicted higher mortality in Copenhagen (Ellervik 2014), though pooled cohorts showed no association across ferritin quarters (Ellervik 2014). Net, indirect body-iron signals lack trial confirmation.

Magnitude: Iron supplement use HR 1.10 (95% CI 1.03–1.17), absolute risk increase 3.9% (Mursu 2011); 0.70 fewer years of parental lifespan per 1-SD (standard deviation, the typical spread around the average) higher genetically predicted serum iron (95% CI 0.24–1.17) (Daghlas 2021); ferritin ≥200 versus <200 μg/L, all-cause mortality HR 1.1 (95% CI 1.1–1.2) (Ellervik 2014); highest versus reference ferritin quarter in pooled cohorts, odds ratio 1.0 (95% CI 0.9–1.1) (Ellervik 2014).

Organ damage from overload in hemochromatosis

People homozygous (carrying two copies) for HFE C282Y over-absorb iron, and supplements add to the load, damaging liver, joints and pancreas. Men are affected far more than women. Indirect: these studies measured genetic iron loading, not supplementation.

Magnitude: Iron-overload-related disease in 28.4% of homozygous men versus 1.2% of women (Allen 2008); over 7 years, 15.7% of homozygous men developed an associated condition versus 5.0% without the variant (Pilling 2019).

Neurodegeneration linked to brain iron

Iron accumulates in brain regions affected by Parkinson’s and Alzheimer’s disease. HFE C282Y homozygous men had more brain iron (Atkins 2021) and more incident dementia (Atkins 2021). Indirect: no study links supplements to dementia.

Magnitude: Incident dementia HR 1.83 (95% CI 1.23–2.72) in C282Y homozygous men versus no HFE variants (Atkins 2021), with no association in women (Atkins 2021).

Cancer linked to higher iron stores

Excess iron may promote cancer through oxidative DNA damage. In the FeAST trial, lowering iron by blood removal reduced new internal-organ cancers (Zacharski 2008). A meta-analysis of observational studies linked higher intake of heme iron (iron from meat and fish) to colorectal cancer (Fonseca-Nunes 2014). Indirect: neither studied supplements.

Magnitude: New internal-organ cancers in 38 of 636 with iron reduction versus 60 of 641 controls (HR 0.65, 95% CI 0.43–0.97) (Zacharski 2008); colorectal cancer RR 1.08 (95% CI 1.00–1.17) per 1 mg/day more heme iron (Fonseca-Nunes 2014).

Venous thromboembolism linked to higher iron status

Venous thromboembolism (blood clots in deep veins or the lungs) can be fatal. A Mendelian randomization study (using gene variants as natural experiments) found genetically higher iron status raised its risk (Gill 2019) but lowered carotid plaque (neck-artery fatty deposits) (Gill 2019). Indirect: genetic iron levels, not supplementation, were studied.

Magnitude: Venous thromboembolism OR 1.37 (95% CI 1.14–1.66) per 1-SD higher genetically predicted serum iron (Gill 2019).

Type 2 diabetes linked to higher iron stores ⚠️ Conflicted

Excess iron may damage insulin-producing cells. A meta-analysis of prospective cohorts linked higher ferritin and heme iron intake to type 2 diabetes (Bao 2012) but found no association with supplemental iron (Bao 2012). Indirect: the positive signal concerns body and dietary iron. Net, cohorts show no excess with supplement use.

Magnitude: Highest versus lowest ferritin, type 2 diabetes RR 1.63 (95% CI 1.03–2.56) after adjustment for inflammatory markers (Bao 2012); highest versus lowest heme iron intake RR 1.33 (95% CI 1.19–1.48) (Bao 2012).

Lasting skin staining after infusion leakage

Intravenous iron leaking out of the vein (extravasation) can stain the skin brown. The Injectafer label warns the staining may be long lasting (Injectafer label). A hospital quality-improvement report calls it rare but potentially permanent (Crowley 2020); a case report documents it after ferric derisomaltose (Shi 2023).

Magnitude: Injection-site discoloration in 4 of 304 patients given ferric carboxymaltose in the FAIR-HF trial, sponsored by maker Vifor Pharma; the paper gives no placebo-group rate (Anker 2009).

Airway and esophageal injury from lodged tablets

An iron tablet that is inhaled (aspiration) or lodges in the esophagus releases iron onto the lining and causes caustic burns. Case reports document ferrous sulfate esophageal injury in a 94-year-old man (Nasir 2020), permanent bronchial narrowing after aspiration (Venci 2014) and death three weeks after aspiration (Hojberg 2024).

Magnitude: Not quantified in available studies. Only case reports exist, so no incidence or comparison-group rate is available.

Speculative 🟨

No risk is graded Speculative: the cell and animal data on iron-driven oxidative damage and ferroptosis concern the same harms already graded above on human data.

Risk-Modifying Factors

  • Genetic variants: HFE C282Y homozygosity, found in 1 in 156 UK Biobank participants of European ancestry (Pilling 2019), sharply raises overload risk (Pilling 2019); compound heterozygotes (one copy each of C282Y and H63D) show only modest excess morbidity (Pilling 2019).
  • Baseline biomarkers: High ferritin or transferrin saturation (share of iron-transport capacity in use) signals existing overload; ferritin ≥1,000 μg/L in homozygous men tracked with fatigue (Allen 2008) and liver disease (Allen 2008). Vitamin D deficiency raises hypophosphatemia risk with ferric carboxymaltose (Injectafer label).
  • Sex: Menstruation protects against overload; men and postmenopausal women accumulate iron. Overload disease affected 28.4% of homozygous men versus 1.2% of women (Allen 2008).
  • Pre-existing conditions: Inflammatory bowel disease raises hypophosphatemia risk with ferric carboxymaltose (Injectafer label). In thalassemia (an inherited anemia often needing transfusions), a review identifies cardiac iron overload as the main cause of illness and death (Borgna-Pignatti 2005).
  • Age: In people over 80, gastrointestinal effects rose with dose (Rimon 2005). The mortality signal came from older women (Mursu 2011).

Key Interactions & Contraindications

Documented interactions:

  • Levothyroxine: Ferrous sulfate taken with thyroxine raised TSH (thyroid-stimulating hormone) from 1.6 to 5.4 mU/L over 12 weeks by binding the hormone, reducing replacement efficacy (Campbell 1992). Common practice separates doses by at least 4 hours.
  • Levodopa (carbidopa-levodopa): Ferrous sulfate cut peak levodopa levels by 55% (Campbell 1989) and AUC (area under the curve, total drug exposure) by 51% through chelation (binding into an unabsorbable complex), risking poorer Parkinson’s control (Campbell 1989). A 2-hour gap is usual.
  • Tetracyclines (a class of broad-spectrum antibiotics; doxycycline, oxytetracycline, tetracycline): Ferrous sulfate seriously impaired antibiotic absorption, risking treatment failure (Neuvonen 1970). Doses are usually separated by at least 3 hours.
  • Fluoroquinolones (a class of synthetic antibiotics; ciprofloxacin, levofloxacin): Ferrous sulfate lowered ciprofloxacin AUC from 14.5 to 5.4 μg·h/mL, below effective levels for many bacteria (Polk 1989). The antibiotic is usually taken 2 hours before or 6 hours after iron.
  • Cefdinir (an oral cephalosporin antibiotic): Iron taken together cut cefdinir AUC from 10.3 to 0.78 μg·h/mL through chelation, risking treatment failure (Ueno 1993). Iron given 3 hours later still lowered later absorption (Ueno 1993), so wide separation is usual.
  • Integrase inhibitors (drugs blocking DNA insertion by HIV, the human immunodeficiency virus; dolutegravir, bictegravir): Ferrous fumarate taken together fasting cut dolutegravir AUC by 54% (Song 2015), risking poorer viral control; dolutegravir 2 hours before iron, or both with a meal, counteracted this (Song 2015).
  • Penicillamine: Ferrous sulfate cut penicillamine plasma levels to 35% of the fasting value (Osman 1983), risking reduced efficacy in Wilson’s disease (inherited copper overload) or rheumatoid arthritis. Doses are usually separated by at least 2 hours.
  • Carbamazepine (an antiseizure drug): Iron supplement use was associated with 33% lower carbamazepine bioavailability in nursing home residents (Ahn 2018), risking breakthrough seizures. Separating doses and checking carbamazepine blood levels is usual.
  • Methyldopa (a blood pressure drug): Ferrous sulfate cut methyldopa absorption from 29.1% to 7.88% (Campbell 1988), and blood pressure rose in four of five treated patients after 2 weeks of iron (Campbell 1988), risking poorer control. Separating doses is usual.
  • Captopril (an angiotensin-converting enzyme inhibitor that lowers blood pressure): Ferrous sulfate taken together cut unconjugated captopril AUC by 37% (Schaefer 1998), without a significant blood pressure change (Schaefer 1998), risking lower drug exposure. Separating doses is usual.
  • Mycophenolate mofetil (an immunosuppressant used after transplantation): Iron taken together sharply lowered mycophenolic acid exposure in one trial (Morii 2000), while another found no interaction (Ducray 2006); lower exposure would risk rejection, so doses are often separated.
  • Proton pump inhibitors (stomach-acid-reducing drugs; omeprazole, pantoprazole): Acid suppression reduced non-heme (plant-type) iron absorption (Hutchinson 2007) and cut yearly blood removal needs in hemochromatosis from 2.5 to 0.5 L (Hutchinson 2007), weakening response to oral iron; ferritin follow-up detects this.
  • Calcium supplements and antacids (calcium carbonate, aluminum-magnesium hydroxide): 300–600 mg calcium reduced iron absorption by 50–60% (Hallberg 1991); calcium carbonate antacid lowered the plasma iron rise by 67% (O’Neil-Cutting 1986), aluminum-magnesium hydroxide did not (O’Neil-Cutting 1986). Calcium blunts repletion; a 2-hour gap is usual.
  • Zinc supplements: A single 60 mg ferrous sulfate dose lowered zinc absorption from 26.9% to 21.7% in lactating women (Chung 2002), risking poorer zinc status with long-term combined use. Taking the two at different times is common practice.
  • Tea, coffee and cocoa: Beverages rich in polyphenols (plant compounds that bind iron) reduced iron absorption by 50–90% (Hurrell 1999), black tea by 79–94% (Hurrell 1999), blunting repletion. Iron is usually taken at least 1 hour before these drinks.
  • Vitamin C (additive effect tested): No interaction found on efficacy: adding 200 mg vitamin C to oral iron did not change the hemoglobin response (difference 0.16 g/dL, 95% CI −0.03 to 0.35) (Li 2020).
  • Turmeric: No interaction found: 0.5 g turmeric did not inhibit iron absorption from a meal (Tuntipopipat 2006).

Theoretical interactions (inferred from mechanism, not studied in humans):

  • Iron-containing multivitamins and fortified products: Inferred from additive iron intake; stacking products can push total intake past the tolerable upper limit and add gastrointestinal effects; counting iron across all products avoids this.
  • Iron chelators (deferasirox, deferiprone, deferoxamine): Inferred from opposing mechanisms; supplemental iron counteracts chelation therapy for overload, so supplements are generally withheld.

Populations who should avoid Iron:

  • Hereditary hemochromatosis or HFE C282Y homozygosity with raised iron stores: Overload disease affected 28.4% of homozygous men (Allen 2008), with ferritin ≥1,000 μg/L tracking with liver disease (Allen 2008).
  • Transfusion-dependent anemias such as thalassemia major: A review identifies cardiac iron overload as the main cause of illness and death (Borgna-Pignatti 2005).
  • Children aged 1–35 months in high-malaria settings without screening: Routine iron and folic acid made death or hospital treatment for an adverse event 12% more likely (Sazawal 2006).
  • Known hypersensitivity to Injectafer (ferric carboxymaltose) or its components: Contraindicated by the product label (Injectafer label).
  • Anemia without iron deficiency (normal or high ferritin): Inferred from mechanism: iron cannot correct the anemia and accumulates; no trial data.

Risk Mitigation Strategies

Doses, timings and thresholds below follow common practice unless cited.

  • Pre-treatment testing: Measuring ferritin, transferrin saturation, hemoglobin and CRP (C-reactive protein, an inflammation marker) first prevents iron use without deficiency and the overload and mortality concerns above.
  • Alternate-day single morning dose: 60 mg on alternate days gave higher absorption than consecutive days (Stoffel 2017), and daily dosing raised gastrointestinal side effects (LPR, longitudinal prevalence ratio, share of symptom days: 1.56) versus alternate days (von Siebenthal 2023).
  • Gentler form or lower dose: In a meta-analysis, bisglycinate caused fewer gastrointestinal events in pregnant women (incidence rate ratio, relative event rate: 0.36) (Fischer 2023); in octogenarians, 15 mg daily matched higher doses with fewer side effects (Rimon 2005).
  • Stopping at repletion: Rechecking ferritin after 8–12 weeks and reassessing above 200 μg/L, where Copenhagen data showed higher mortality (Ellervik 2014), limits overload risk.
  • Genotyping when saturation is high: European Association for the Study of the Liver (EASL) guidance, whose hepatologist members bill for overload care, sets HFE testing at transferrin saturation above 45% (women) or 50% (men) (EASL 2022), preventing overload damage.
  • Child-proof storage: Child-resistant packaging stored out of reach prevents fatal pediatric poisoning.
  • Upright swallowing with water: Taking tablets upright with a full glass of water, or a liquid form when swallowing is impaired, lowers the risk of a lodged or inhaled tablet injuring the esophagus or airway.
  • Phosphate checks with ferric carboxymaltose: The label calls for serum phosphate checks before a repeat course in at-risk patients or within three months of the prior course (Injectafer label), preventing hypophosphatemia and osteomalacia.
  • Supervised infusion: Observation for at least 30 minutes after intravenous iron, with treatment available, is required (Injectafer label), mitigating severe infusion reactions.
  • Deferring infusion during active infection: Deferring intravenous iron until infections resolve limits the possible infection excess.

Therapeutic Protocol

Timing, titration and duration below reflect common practice unless cited.

  • Deficiency confirmed first: Treatment is reserved for low ferritin or iron-deficiency anemia; the Attia approach starts from ferritin testing and matches diet, tablets or infusion to the person (Peter Attia AMA #58).
  • Alternate-day oral regimen: 60 mg iron as ferrous sulfate on alternate mornings (Stoffel 2017) or 100 mg on alternate days (von Siebenthal 2023); the AGA, whose members bill for infusions, advises once daily at most (DeLoughery 2024).
  • Daily regimen for fatigue: 80 mg elemental iron daily for 4 weeks (Verdon 2003) or as prolonged-release ferrous sulfate for 12 weeks (Vaucher 2012).
  • Maintenance intake: RDA (recommended dietary allowance) 8 mg for men and women over 50 (NIH Office of Dietary Supplements fact sheet) and 18 mg for women aged 19–50 (NIH Office of Dietary Supplements fact sheet).
  • Upper limit: The tolerable upper limit for adults is 45 mg daily (NIH Office of Dietary Supplements fact sheet).
  • Form choice, conventional versus integrative: The AGA, whose members bill for infusions, prefers inexpensive ferrous sulfate (DeLoughery 2024); bisglycinate, popular in integrative practice, caused fewer gastrointestinal events in pregnant women in a meta-analysis (Fischer 2023).
  • Vitamin C, competing views: The AGA, whose members bill for infusions, advises adding vitamin C to oral iron (DeLoughery 2024); a randomized trial found vitamin C added no hemoglobin gain (Li 2020).
  • Intravenous route: The AGA, whose members bill for infusions, reserves it for intolerance, failed oral therapy or poor absorption (DeLoughery 2024); FAIR-HF2 gave ferric carboxymaltose up to 2,000 mg, then 500 mg every 4 months (Anker 2025).
  • Time of day: The absorption trials gave iron at 08:00 in the morning (Stoffel 2017); taking it on an empty stomach, away from coffee, tea, calcium and medicines, is common practice.
  • Half-life: Iron has no elimination half-life; consecutive-day dosing kept serum hepcidin higher than alternate-day dosing (Stoffel 2017), the basis for alternate days.
  • Single versus split dose: Twice-daily split dosing raised hepcidin (Stoffel 2017) without improving absorption (Stoffel 2017), favoring one dose.
  • Genetic variants: In HFE C282Y homozygotes, iron use is usually confined to documented deficiency, with close ferritin follow-up.
  • Sex: Menstruating women have more than double men’s allowance (NIH Office of Dietary Supplements fact sheet).
  • Age: In people over 80, 15 mg daily corrected anemia as well as 150 mg (Rimon 2005).
  • Baseline biomarkers: Benefit concentrates at ferritin ≤50 μg/L (Verdon 2003); a Lancet review notes that inflammation (raised CRP) limits oral absorption, favoring intravenous iron (Pasricha 2021).
  • Pre-existing conditions: After bariatric surgery or in inflammatory bowel disease with active inflammation, the AGA, whose members bill for infusions, prefers intravenous iron (DeLoughery 2024).

Discontinuation & Cycling

  • Short-term by design: Iron is a course, not a lifelong supplement, unless losses continue (heavy menstruation, frequent donation); courses typically end once ferritin is replete.
  • Withdrawal effects: None are known; stopping simply ends further loading.
  • Tapering: Not required; shifting to dietary intake or a low maintenance dose is common.
  • Cycling: No cycling is needed for efficacy; repeat courses follow ferritin. In HEART-FID, repeat doses were given as needed based on iron indexes (Mentz 2023).
  • Follow-up after stopping: Rechecking ferritin 3–6 months after a course detects recurrence and prompts a search for its cause.

Sourcing and Quality

  • Elemental iron content: Dosing uses elemental iron, not salt weight: ferrous fumarate is 33% iron (NIH Office of Dietary Supplements fact sheet), ferrous sulfate 20% (NIH Office of Dietary Supplements fact sheet) and ferrous gluconate 12% (NIH Office of Dietary Supplements fact sheet).
  • Forms: Salts (sulfate, gluconate, fumarate) are cheapest; bisglycinate, polysaccharide-iron complex and heme iron polypeptide aim for better tolerance; intravenous products such as Injectafer are prescription-only (Injectafer label).
  • Third-party testing: USP (United States Pharmacopeia) Verified or NSF (NSF International certification) marks and ConsumerLab testing confirm labeled content and purity.
  • Reputable brands: Widely tested examples include Thorne Iron Bisglycinate, Life Extension Iron Protein Plus and pharmacy ferrous sulfate tablets; these are examples, not endorsements.
  • Packaging: Child-resistant, unit-dose packaging reduces poisoning risk (Tenenbein 2005).
  • Hidden iron in multivitamins: Iron-free multivitamins exist for men and postmenopausal women who are not deficient.

Practical Considerations

  • Time to effect: Hemoglobin rose about 1.8–2.0 g/dL within 2 weeks in iron-deficiency anemia (Li 2020); fatigue improved within 4 weeks (Verdon 2003).
  • Common pitfalls: Taking iron without testing, daily split doses, taking it with coffee, calcium or levothyroxine, continuing indefinitely, reading ferritin during inflammation, and leaving the cause unexplored, although a Lancet review holds that an underlying cause should be sought in all patients (Pasricha 2021).
  • Regulatory status: Oral iron is sold without prescription in the US, with a mandatory overdose warning (21 CFR 101.17); Injectafer is FDA (US Food and Drug Administration) approved for iron deficiency in heart failure (Injectafer label).
  • Cost and access: Oral iron costs cents per dose; intravenous iron requires a clinic and costs far more.
  • Structural incentives: Insurers and national health systems have a financial incentive to favor cheap oral iron, while intravenous iron makers funded major heart failure trials; both can shape guidelines and research priorities.

Interaction with Foundational Habits

  • Sleep: Indirect. Iron eases restless legs, a common cause of disturbed sleep, but in a Cochrane review subjective sleep quality did not differ from placebo (Trotti 2019). No direct effect on sleep architecture is known.
  • Nutrition: Direct. Calcium (Hallberg 1991) and tea or coffee (Hurrell 1999) blunt absorption. Plant-based diets supply only the less absorbable plant iron.
  • Exercise: Direct. Regular training is associated with lower stores: Finnish men exercising more than 3 sessions weekly had 19.9% lower ferritin (Lakka 1994). Taking iron in the morning, apart from the post-exercise hepcidin rise, is common practice.
  • Stress management: Indirect. In a meta-analysis of non-anemic iron-deficient participants, iron improved anxiety symptoms (Fiani 2025); no direct effect on cortisol is known.

Monitoring Protocol & Defining Success

Baseline testing before starting establishes whether deficiency exists and rules out overload: ferritin, transferrin saturation, hemoglobin with a complete blood count, and CRP to interpret ferritin, taken fasting in the morning. HFE genotyping is added when transferrin saturation is high or a relative has hemochromatosis, and serum phosphate before intravenous ferric carboxymaltose.

Ongoing monitoring follows a set cadence: hemoglobin at 2–4 weeks to confirm response, ferritin and transferrin saturation at 8–12 weeks to decide on stopping, then every 6–12 months while risk factors persist. With repeated ferric carboxymaltose, phosphate is checked before each repeat course. Success means symptoms resolve and ferritin sits in the target band without saturation rising toward overload.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Serum ferritin 50–200 μg/L (lower bound from Verdon 2003 fatigue trial; upper bound from Ellervik 2014 mortality cohort) Marker iron is expected to change; safety check for excess Lower bound: fatigue benefit confined to ≤50 μg/L (Verdon 2003); upper bound: higher mortality at ≥200 μg/L (Ellervik 2014). Conventional reference range roughly 15–150 μg/L (women) and 30–400 μg/L (men), laboratory-dependent. Inflammation raises ferritin; pair with CRP.
Transferrin saturation 20–50% (standard reference range) Safety check for overload; marker iron changes Fasting morning sample. Below 20% marks iron-restricted supply, as used in FAIR-HF2 eligibility (Anker 2025). Persistently high values prompt HFE testing.
Hemoglobin (complete blood count) 12.0–15.5 g/dL women, 13.5–17.5 g/dL men (standard reference range) Marker iron is expected to change in anemia Rises within 2 weeks of treatment (Li 2020); a flat response suggests non-iron causes or poor absorption.
Serum phosphate (intravenous ferric carboxymaltose only) 2.5–4.5 mg/dL (standard reference range) Safety check; low values change the iron product Checked before repeat courses in at-risk patients (Injectafer label).
HFE genotype (C282Y, H63D) No established target; record genotype once Safety check; homozygosity stops routine use One-time test; C282Y homozygosity carries the main overload risk (Pilling 2019).

Qualitative markers:

  • Fatigue and daytime energy
  • Exercise tolerance and breathlessness on exertion
  • Restless legs symptoms at night
  • Concentration and mental clarity
  • Gastrointestinal tolerance (nausea, constipation, stool changes)

Emerging Research

  • ICONIC-HF (NCT06929806): Phase 3, 1,900 iron-deficient patients with chronic heart failure, ferric derisomaltose versus no intravenous iron; primary endpoint cardiovascular deaths and heart failure hospitalizations at 52 weeks; manufacturer-sponsored, recruiting. A positive result would firm up the heart failure benefit; a null result would weaken it further.
  • INFERRCT (NCT05759078): Phase 4, 1,000 iron-deficient patients after recent myocardial infarction, ferric carboxymaltose versus placebo; primary endpoints include all-cause death and heart failure events over up to 36 months; recruiting. Positive would extend benefit beyond heart failure; null would confine it.
  • IRONCARE (NCT07659184): Phase 4, 528 adults aged 75 or older with hip fracture, intravenous ferric derisomaltose versus alternate-day oral ferrous sulfate versus placebo; primary endpoints fatigue, hemoglobin and safety; not yet recruiting. Positive would support iron for recovery in older adults; null would weaken that case.
  • INFUSE-HFpEF (NCT07686692): Phase 4, 300 adults aged 65 or older with heart failure with preserved ejection fraction (stiff-heart failure), ferric derisomaltose versus placebo; primary endpoint a composite of death, hospitalization and symptom score at 6 months; not yet recruiting. Positive would add a new group; null would limit benefit to reduced pumping function.
  • Iron and human lifespan genetics: Genetic analyses implicate heme metabolism in aging (Timmers 2020) and suggest harm from higher serum iron (Moksnes 2022) but weak protection at its very low end (Moksnes 2022). Trials of keeping iron low-normal in healthy adults could weaken or strengthen supplementation in replete people.
  • Brain iron lowering: In early Parkinson’s disease, the iron chelator deferiprone worsened symptoms versus placebo (Devos 2022), cautioning against assuming that less brain iron is always better.

Conclusion

Iron is an essential mineral that health-focused adults meet from two sides: as a fix for deficiency and as a possible accelerant of aging when stores run high. The evidence is strongest where deficiency is real. Correcting it restores blood levels, eases fatigue in women with low stores even before anemia appears, relieves restless legs and, given by infusion, reduces hospital stays in heart failure. Exercise capacity improves where deficiency limits oxygen delivery; mental sharpness gains are smaller; people with full stores show no measurable gain.

The risks follow the same logic. Digestive side effects are common with tablets and are the main reason people stop. Infusions carry rare but serious allergic-type reactions and some infection risk, and one infusion product can deplete a mineral bones depend on. Accidental overdose endangers young children in the household. For people who are not deficient, the concern shifts to accumulation: inherited overload, links between high stores and earlier death in population and genetic studies, and brain iron in later life. These signals lack trial confirmation, so they remain uncertain.

The evidence base mixes solid trials in narrow groups with weaker population and genetic data on long-term harm. Makers of the products tested funded much of the heart failure, fatigue and infusion-safety evidence and part of the restless legs evidence, and the societies behind the cited guidance have members paid for infusions or overload care. The picture favors iron as a targeted correction guided by testing rather than as a general longevity supplement.

Top - Benefits - Risks - Protocol